Article Figures & Data
Tables
- Table 1.
SGLT2-I, GLP1-RA, And GIP/GLP-1 RA Use in Practice for Patients with Type 2 Diabetes
Therapy and dose range eGFR Cut-off for initiation for glycemic benefit Additional indications for adults with type 2 diabetes Median average wholesale price SGLT2-Inhibitors Bexagliflozin (Brenzavvy), 20 mg PO once daily 30 mL/min n/a Canagliflozin (Invokana), 100 to 300 mg PO once daily 30 mL/min Established CVD: risk reduction of MACE
Diabetic nephropathy with albuminuria >300 mg/d: risk reduction of ESKD, serum creatinine doubling, CV death, and HHF
$684 Dapagliflozin (Farxiga), 5 to 10 mg PO once daily 45 mL/min Established CVD or multiple CV risk factors: risk reduction of HHF
HFrEF: risk reduction of CV death and HHF
$659 Empagliflozin (Jardiance), 10 to 25 mg PO once daily 30 mL/min Established CVD: risk reduction CV death
HFrEF and HFpEF: risk reduction CV death and HHF
$685 Ertugliflozin (Steglatro), 5 to 15 mg PO once daily 45 mL/min $390 GLP-1 receptor agonists and GIP/GLP-1 receptor agonists Dulaglutide (Trulicity), 0.75- 4.5 mg weekly injection n/a Established CVD or multiple CV risk factors: risk reduction MACE
$1,064 Exenatide (Byetta), 5 to 10 mcg twice daily injection 30 mL/min $961 Exenatide XR (Bydureon BCise),2 mg weekly injection 30 mL/min $936 Liraglutide (Victoza), 0.6-1.8 mg weekly injection n/a Established CVD: risk reduction MACE
$1,278 Semaglutide (Ozempic), 0.25-2 mg weekly injection n/a Established CVD: risk reduction MACE
$1,070 Semaglutide (Rybelsus), 7 to 14 mg PO once daily n/a $1,070 GIP/GLP-1 receptor agonists Tirzepatide n/a $1,169 Abbreviations: eGFR, estimated glomerular filtration rate (mL/min/1.73 m2); MACE, major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke); ESKD, end-stage kidney disease; HHF, hospitalization for heart failure; HFrEF, heart failure with reduced ejection fraction; CKD, chronic kidney disease; HFpEF, Heart failure with preserved ejection fraction.
